The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Buprenorphine: A Unique Drug with Complex Pharmacology
Open accessAbstract
Buprenorphine, an opioid with mixed agonist-antagonist activity at classical opioid receptors, has been approved recently for the treatment of opioid dependency. Buprenorphine is also used as an analgesic. The buprenorphine dose-response curve is sometimes submaximal, or even bell-shaped, in nociceptive assays, depending upon the nature and intensity of the noxious stimulus. Moreover, buprenorphine, when administered with full agonists, such as morphine, antagonizes the action of these drugs. Partial agonism at the mu opioid receptor and, in some cases, antagonism at the kappa or delta opioid receptor have been considered as possible underlying mechanisms for the ceiling effect and bell-shaped dose-response curve of buprenorphine. While ceiling effects can be explained by partial agonist activity of buprenorphine, the bell-shaped dose-response curve cannot be a consequence of this property of the drug. Recently, buprenorphine has been shown to activate the opioid receptor-like (ORL-1; also known as NOP) receptor. Supraspinal activation of the ORL-1 receptor counteracts the antinociceptive and rewarding actions of morphine, raising the possibility that these actions of buprenorphine can also be altered by its ability to concomitantly activate the ORL-1 receptor. The use of molecular biological techniques has advanced our knowledge regarding the role of opioid receptors in modulation of pain and reward. In particular, generation of opioid receptor knockout mice has proven useful in this regard. Indeed, using knockout mice, we have recently shown that the antinociceptive effect of buprenorphine mediated primarily by the mu opioid receptor is attenuated by the ability of the drug to activate the ORL-1 receptor. Thus, the goal of this review is to provide evidence demonstrating that the ORL-1 receptor plays a functional role not only in the antinociceptive effect of buprenorphine but also in other actions of the drug as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
ROBINSON, T., & BECKER, J. (1986) · Brain Research · doi:10.1016/s0006-8993(86)80193-7 · Cited by 2,106
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Kalivas, P. W., & Stewart, J. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,019
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., et al. (1995) · Nature · doi:10.1038/377532a0 · Cited by 1,912
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., & Civelli, O. (1995) · Science · doi:10.1126/science.270.5237.792 · Cited by 1,821
The psychology and neurobiology of addiction: an incentive–sensitization view
Robinson, T. E., & Berridge, K. C. (2000) · Addiction · doi:10.1046/j.1360-0443.95.8s2.19.x · Cited by 1,507
Cloning of a Delta Opioid Receptor by Functional Expression
Evans, C. J., Keith, D. E., Morrison, H., Magendzo, K., & Edwards, R. H. (1992) · Science · doi:10.1126/science.1335167 · Cited by 1,233
ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization
Mollereau, C., Parmentier, M., Mailleux, P., Butour, J.-L., Moisand, C., Chalon, P., Caput, D., Vassart, G., & Meunier, J.-C. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80235-1 · Cited by 1,077
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
SIMULTANEOUS QUANTITATIVE ASSESSMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE
WAY, E. L., LOU, H. H., & SHEN, F.-H. (1969) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28317-3 · Cited by 673
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.
Yasuda, K., Raynor, K., Kong, H., Breder, C. D., Takeda, J., Reisine, T., & Bell, G. I. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6736 · Cited by 618
Bunzow, J. R., Saez, C., Mortrud, M., Bouvier, C., Williams, J. T., Low, M., & Grandy, D. K. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00561-3 · Cited by 607
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Self-citationOpioids: first lessons from knockout mice
Kieffer, B. L. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01279-6 · Cited by 489
The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family
Mogil, J. S., & Pasternak, G. W. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01502-3 · Cited by 441
cDNA cloning and regional distribution of a novel member of the opioid receptor family
Fukuda, K., Kato, S., Mori, K., Nishi, M., Takeshima, H., Iwabe, N., Miyata, T., Houtani, T., & Sugimoto, T. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80603-9 · Cited by 410
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 1×
“This opioid analgesic, which was the focus of many clinical trials for the treatment of opioid dependency [32,47,49,50,59], even in opiate addicts with a history of cocaine co-abuse [72, 85,86], has recently been approved for the treatment of opioid dependency [30].”
BackgroundBuprenorphine: A Review of its Pharmacological Properties and Therapeutic Efficacy
Heel, R. C., Brogden, R. N., Speight, T. M., & Avery, G. S. (1979) · Drugs · doi:10.2165/00003495-197917020-00001 · Cited by 398
Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
Meunier, J.-C. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01411-8 · Cited by 388
cDNA Cloning of an orphan opiate receptor gene family member and its splice variant
Wang, J. B., Johnson, P. S., Imai, Y., Persico, A. M., Ozenberger, B. A., Eppler, C. M., & Uhl, G. R. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00557-5 · Cited by 381
Orphanin FQ is a functional anti-opioid peptide
Mogil, J. S., Grisel, J. E., Reinscheid, R. K., Civelli, O., Belknap, J. K., & Grandy, D. K. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00338-7 · Cited by 375
A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Huang, P., Kehner, G. B., Cowan, A., & Liu-Chen, L.-Y. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29586-0 · Cited by 340
Self-citationChen, Y., Fan, Y., Liu, J., Mestek, A., Tian, M., Kozak, C. A., & Yu, L. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00560-5 · Cited by 333
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200041006 · Cited by 303
Molecular cloning and functional expression of a mu-opioid receptor from rat brain.
Chen, Y., Mestek, A., Liu, J., et al. (1993) · PubMed · Cited by 243
Lewis, J. W. (1985) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(85)90067-5 · Cited by 241
Tian, J., Xu, W., Fang, Y., Mogil, J. S., Grisel, J. E., Grandy, D. K., & Han, J. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700942 · Cited by 235
Functional antagonism of μ-, δ- and κ-opioid antinociception by orphanin FQ
Mogil, J. S., Grisel, J. E., Zhangs, G., Belknap, J. K., & Grandy, D. K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12917-7 · Cited by 227
Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro
Connor, M., Vaughan, C. W., Chieng, B., & Christie, M. J. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb16080.x · Cited by 225
Picard, P. R., Tramèr, M. R., McQuay, H. J., & Moore, A. R. (1997) · Pain · doi:10.1016/s0304-3959(97)00040-7 · Cited by 223
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic
WALSH, S. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00056-5 · Cited by 219
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
Self-citationOpiate tolerance and dependence: receptors, G-proteins, and antiopiates
Harrison, L. M., Kastin, A. J., & Zadina, J. E. (1998) · Peptides · doi:10.1016/s0196-9781(98)00126-0 · Cited by 204
Kawamoto, H., Ozaki, S., Itoh, Y., Miyaji, M., Arai, S., Nakashima, H., Kato, T., Ohta, H., & Iwasawa, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990517p · Cited by 204
Matthes, H. W. D., Smadja, C., Valverde, O., Vonesch, J.-L., Foutz, A. S., Boudinot, E., Denavit-Saubié, M., Severini, C., Negri, L., Roques, B. P., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07285.1998 · Cited by 199
Sittl, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90019-1 · Cited by 186
Knoflach, F., Reinscheid, R. K., Civelli, O., & Kemp, J. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-21-06657.1996 · Cited by 181
DUM, J. E., & HERZ, A. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb10473.x · Cited by 176
Murphy, N. P., Ly, H. T., & Maidment, N. T. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00322-3 · Cited by 173
A Cellular Mechanism for the Bidirectional Pain-Modulating Actions of Orphanin FQ/Nociceptin
Pan, Z. Z., Hirakawa, N., & Fields, H. L. (2000) · Neuron · doi:10.1016/s0896-6273(00)81183-6 · Cited by 158
Orphanin FQ/nociceptin blocks acquisition of morphine place preference
Murphy, N. P., Lee, Y., & Maidment, N. T. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01425-0 · Cited by 158
Heidbreder, C. A., Goldberg, S. R., & Shippenberg, T. S. (1993) · Brain Research · doi:10.1016/0006-8993(93)90228-f · Cited by 151
Shippenberg, T. S., LeFevour, A., & Heidbreder, C. A. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12305-7 · Cited by 149
Ueda, H., Yamaguchi, T., Tokuyama, S., Inoue, M., Nishi, M., & Takeshima, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00832-x · Cited by 147
Effect of nociceptin/orphanin FQ on the rewarding properties of morphine
Ciccocioppo, R., Angeletti, S., Sanna, P. P., Weiss, F., & Massi, M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00590-2 · Cited by 142
Kalivas, P. W., & Duffy, P. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb03036.x · Cited by 139
Substitution Pharmacotherapies for Opioid Addiction: From Methadone to LAAM and Buprenorphine
Ling, W. W., Rawson, R. A., & Compton, M. A. (1994) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1994.10472259 · Cited by 135
Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
Sadée, W., Rosenbaum, J. S., & Herz, A. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33306-9 · Cited by 118
Schottenfeld, R. S., Pakes, J., Ziedonis, D. M., & Kosten, T. R. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90258-f · Cited by 118
Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ
Morgan, M. M., Grisel, J. E., Robbins, C. S., & Grandy, D. K. (1997) · Neuroreport · doi:10.1097/00001756-199711100-00003 · Cited by 112
Brown, E. E., Finlay, J. M., Wong, J. T., Damsma, G., & Fibiger, H. C. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23126-3 · Cited by 112
Cloning of a human κ opioid receptor from the brain
Zhu, J., Chen, C., Xue, J.-C., Kunapuli, S. P., DeRiel, J. K., & Liu‐Chen, L. (1995) · Life Sciences · doi:10.1016/0024-3205(94)00507-o · Cited by 109
Giannuario, A. D., Pieretti, S., Catalani, A., & Loizzo, A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00579-0 · Cited by 105
Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice
Leander, J. D. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90543-2 · Cited by 104
Modulation of drug-induced sensitization processes by endogenous opioid systems
Spanagel, R. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(94)00176-g · Cited by 104
Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor
Bloms‐Funke, P., Gillen, C., Schuettler, A. J., & Wnendt, S. (2000) · Peptides · doi:10.1016/s0196-9781(00)00252-7 · Cited by 103
Giannuario, A. D., & Pieretti, S. (2000) · Peptides · doi:10.1016/s0196-9781(00)00250-3 · Cited by 99
Lutfy, K., Do, T., & Maidment, N. T. (2001) · Psychopharmacology · doi:10.1007/s002130000609 · Cited by 97
Self-citationLong-term sensitization to the excitatory effects of morphine
Bartoletti, M., Gaiardi, M., Gubellini, G., Bacchi, A., & Babbini, M. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90080-1 · Cited by 94
Agonistic Effect of Buprenorphine in a Nociceptin/OFQ Receptor-Triggered Reporter Gene Assay
Wnendt, S., Krüger, T., Janocha, E., Hildebrandt, D., & Englberger, W. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.2.334 · Cited by 94
Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
Heidbreder, C. A., Babovic‐Vuksanovic, D., Shoaib, M., & Shippenberg, T. S. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12030-2 · Cited by 87
Buprenorphine: An Analgesic with an Expanding Role in the Treatment of Opioid Addiction
Robinson, S. E. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00235.x · Cited by 83
Buprenorphine: Characteristics of binding sites in the rat central nervous system
Villiger, J. W., & Taylor, K. M. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90529-4 · Cited by 68
Accelerated release and production of orphanin FQ in brain of chronic morphine tolerant rats
Li, Y., Zhou, H., Chang, J.-K., & Han, J.-S. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01337-2 · Cited by 67
Delta opioid antagonist effects of buprenorphine in rhesus monkeys
Negus, S. S., Bidlack, J. M., Mello, N. K., Furness, M. S., Rice, K. C., & Brandt, M. R. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200211000-00005 · Cited by 64
Buprenorphine: Demonstration of physical dependence liability
Dum, J., Bläsig, J., & Herz, A. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90163-1 · Cited by 61
Animal and molecular pharmacology of mixed agonist‐antagonist analgesic drugs.
Rance, M. J. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04701.x · Cited by 58
Buprenorphine: Bell-shaped dose-response curve for its antagonist effects
Lizasoaín, I., Leza, J. C., & Lorenzo, P. L. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90452-c · Cited by 54
Morphine tolerance and dependence in nociceptin/orphanin fq transgenic knock-out mice
Kest, B., Hopkins, E., Palmese, C. A., Chen, Z. P., Mogil, J. S., & Pintar, J. E. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00037-9 · Cited by 54
Desipramine in Opioid-Dependent Cocaine Abusers Maintained on Buprenorphine vs Methadone
Oliveto, A. H., Feingold, A., Schottenfeld, R. S., Jatlow, P. I., & Kosten, T. R. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.812 · Cited by 51
Buprenorphine and morphine cause antisiociception by different transduction mechanisms
Wheeler-Aceto, H., & Cowan, A. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90485-9 · Cited by 50
Self-citationBuprenorphine exerts its antinocicepttve activity via μ1-opioid receptors
Kamei, J., Saitoh, A., Suzuki, T., Misawa, M., Nagase, H., & Kasuya, Y. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00078-x · Cited by 50
Hawkinson, J. E., Acosta-Burruel, M., & Espitia, S. A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00904-8 · Cited by 48
Orphanin FQ/nociceptin inhibits morphine withdrawal
Kotlińska, J., Suder, P., Legowska, A., Rolka, K., & Silberring, J. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00648-7 · Cited by 31
Medications for Alcohol, Illicit Drug, and Tobacco Dependence
Litten, R. Z., & Allen, J. P. (1999) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(98)00028-2 · Cited by 29
Budd, K., & Collett, B. J. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg133 · Cited by 26
Binding of buprenorphine to opiate receptors
Villiger, J. W. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90201-6 · Cited by 22
Goodman, C. B., Heyliger, S. O., Emilien, B., Partilla, J. S., Yang, H., Lee, C.-H., Cadet, J. L., & Rothman, R. B. (1998) · Peptides · doi:10.1016/s0196-9781(98)00121-1 · Cited by 21
Lutfy, K., & Maidment, N. T. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703746 · Cited by 16
Self-citationBuprenorphine Blocks ϵ- and μ-Opioid Receptor-Mediated Antinociception in the Mouse
Mizoguchi, H., Spaulding, A., Leitermann, R. J., Wu, H.-E., Nagase, H., & Tseng, L. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048835 · Cited by 16
Finco, G., Polati, E., Gottin, L., et al. (1995) · PubMed · Cited by 6
Office-Based Treatment of Opiate Addiction
Heit, H. A., & Gourlay, D. L. (2003) · New England Journal of Medicine · doi:10.1056/nejm200312253492619 · Cited by 4
Cited by
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Mu Opioids and Their Receptors: Evolution of a Concept
Pasternak, G. W., & Pan, Y.-X. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007138 · Cited by 578
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Biased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
Metadata
- Authors
- Lutfy, K., & Cowan, A.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-10-01
- Volume
- 2
- Issue
- 4
- Pages
- 395-402
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2024940322
- Cited by
- 345
- References
- 90
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.